Previous 10 | Next 10 |
Leaders More news on: Apple Inc., Microsoft Corporation, JPMorgan Chase & Co., Top stock market news, Read more ...
Abiomed, Inc . (NASDAQ: ABMD), a leading provider of breakthrough heart support technologies, today announced that Michael R. Minogue, Chairman, President and Chief Executive Officer, will present at the 38th Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2020 at 12:00 p.m. ...
The stock market continued its bull run this year, with all the major indexes on track to end 2019 with double-digit gains. Stocks are setting new highs despite warnings of a looming recession. The S&P 500 set 19 new all-time highs in 2019, and that's after 18 new highs in 2018. Despi...
Abiomed (NASDAQ: ABMD) has enjoyed tremendous success over the last seven years. At the start of 2013, the company traded at $14 and today its stock price is $183. The medical device maker's main product is the Impella line of heart pumps, devices that are inserted percutaneously (through th...
Abiomed (NASDAQ: ABMD) announces initiation of the ST-Elevation Myocardial Infarction Door-to-Unloading (STEMI DTU) Pivotal Randomized Controlled Trial (RCT), which will explore whether unloading the heart’s left ventricle for 30 minutes with an Impella heart pump prior to opening ...
A pivotal, multi-center clinical trial to explore a promising new therapy to reduce heart failure rates by changing the way heart attack patients are treated is now underway. The first patient has enrolled in the ST-Elevation Myocardial Infarction Door-to-Unloading (STEMI DTU) Pivotal Randomi...
2019 has been a rotten year for Abiomed 's (NASDAQ: ABMD) investors. Shares of the temporary heart pump maker have fallen more than 40% since January in response to a slew of negative headlines. Meanwhile, Abiomed's revenue and net income have continued to grow . The combination has pulled...
Abiomed, Inc. (NASDAQ:ABMD), a leading provider of breakthrough heart support technologies, today announced that Michael R. Minogue, Chairman, President and Chief Executive Officer, will present at the 31 st Annual Piper Jaffray Healthcare Conference on Wednesday, December 4, 2019 at 3:00pm ...
Abiomed ( ABMD +4.8% ) is up on double normal volume after its medical office issued its review of two observational studies presented at the American Heart Association Scientific Sessions that questioned the value proposition of its Impella heart pump. More news on: Abiomed, In...
Abiomed (NASDAQ: ABMD) is committed to improving patient outcomes by performing FDA studies and post-market surveillance, collecting real-world evidence and identifying and sharing best practices. Impella is the most studied mechanical circulatory support device in the history of the FDA ...
News, Short Squeeze, Breakout and More Instantly...
Abiomed (Nasdaq: ABMD) announces the United States Food and Drug Administration (FDA) has approved the version of Impella ECP that will be used in the Impella ECP Pivotal Trial, and the first two patients have been enrolled in the trial. Amir Kaki, MD, director of mechanical circulatory support...
Steel Dynamics Set to Join S&P 500; Super Micro Computer to Join S&P MidCap 400 Steel Dynamics Set to Join S&P 500; Super Micro Computer to Join S&P MidCap 400 PR Newswire NEW YORK , Dec. 19, 2022 /PRNewswire/ -- S&P MidCap 400 constituent...
Abiomed (Nasdaq: ABMD) announces the first three patients in the world have been treated with Impella RP Flex with SmartAssist, Abiomed’s newest heart pump for patients experiencing right heart failure. All three patients have now been successfully weaned off Impella support and two have...